Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
APOE	348	BUTHIONINE SULFOXIMINE	CHEMBL1609891		NCI	12615656
APOE	348	ALBUMIN HUMAN	CHEMBL1201451		DrugBank	17141733, 16554356, 12860569, 12887764, 17553935
APOE	348	SIMVASTATIN	CHEMBL1064		PharmGKB
APOE	348	IRBESARTAN	CHEMBL1513		NCI	12827021
APOE	348	CERIVASTATIN	CHEMBL1477		PharmGKB
APOE	348	RITONAVIR	CHEMBL163		PharmGKB
APOE	348	PREDNISONE	CHEMBL635		NCI	3185288
APOE	348	VITAMIN E	CHEMBL47		NCI	12076219
APOE	348	GINKGO	CHEMBL2108466		NCI	12684092
APOE	348	TRETINOIN	CHEMBL38		NCI	3468509
APOE	348	SOYBEAN OIL	CHEMBL1201485		NCI	3021887
APOE	348	LORAZEPAM	CHEMBL580		NCI	15699298
APOE	348	STAUROSPORINE	CHEMBL388978		NCI	11948667
APOE	348	TROGLITAZONE	CHEMBL408		NCI	15057551
APOE	348	GONADOTROPIN, CHORIONIC	CHEMBL1201509		NCI	1709885
APOE	348	LUTEIN	CHEMBL173929		NCI	11413081
APOE	348	TRIAMCINOLONE	CHEMBL1451		NCI	9150415
APOE	348	GANCICLOVIR	CHEMBL182		NCI	16322528

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
APOE	rs7412	CT	atorvastatin	efficacy	yes	as measured by decreases in LDL-cholestrol.	Genotype CT is associated with increased response to atorvastatin as compared to genotype CC.	16103896	982045529
APOE	rs7412	C	atorvastatin	efficacy	yes	As measured by reduction in LDLc. Association was significant only at high doses.	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.	20031551	827807830
APOE	rs405509	TT	Selective serotonin reuptake inhibitors	efficacy	yes	response measured by HDRS-17 score. Patients received SSRI or SNRI but exact drug not specified.	Genotype TT is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes GG + GT.	32795354	1451284760
APOE	rs429358	T	warfarin	dosage	no		Allele T is not associated with decreased dose of warfarin as compared to allele C.	20072124	982037951
APOE	rs429358	CC	lovastatin	efficacy	no	as measured by decreases in LDL-cholestrol. No significant association was seen between all three genotypes and response.	Genotype CC is not associated with response to lovastatin as compared to genotype TT.	16103896	982045810
APOE	rs7412	T	warfarin	dosage	no		Allele T is not associated with decreased dose of warfarin as compared to allele C.	20072124	982037960
APOE	rs429358	CC + CT	warfarin	dosage	yes	The APOE *e4 was associated with lower warfarin dose. Doses of e4 carriers (41.5±18.5) were 21 % lower than doses of e4 non-carriers (52.5±37.5 mg). This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week.	Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT.	25312789	1444666244
APOE	rs7412	CT + TT	rosuvastatin	efficacy	yes	The minor allele of this SNP is associated with increased fractional LDL-C reduction on rosuvastatin.	Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC.	22331829	1447951982
APOE	rs71352238	CC + CT	rosuvastatin	efficacy	yes	The minor allele of this SNP is associated with decreased LDL-C reduction on rosuvastatin. The mean per allele effect was 4.17 mg/dL.	Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.	22331829	1447951974
APOE	rs7412	CC	warfarin	dosage	yes		Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CT.	28079798	1448567661
APOE	rs7412	C	acenocoumarol	dosage	no		Allele C is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T.	29432897	1449190764
APOE	rs429358	C	acenocoumarol	dosage	yes		Allele C is associated with decreased dose of acenocoumarol in people with venous thromboembolism as compared to allele T.	29432897	1449190950
APOE	rs7412	CT	fluvastatin	efficacy	yes	but only for percentage change in HDL. It was not significant for total cholesterol, LDL or TGs. Effect reported for carrier ApoE*2/*3 vs ApoE*3/*3, and vs ApoE*3/*4 or *4/*4.	Genotype CT is associated with increased response to fluvastatin as compared to genotype CC.	30363031	1450972760
APOE	rs7412	CC	warfarin	dosage	yes		Genotype CC is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes CT + TT.	31854268	1450942212
APOE	rs7412	T	acenocoumarol	dosage	not stated	This variant was not significantly associated with acenocoumarol dose, though it did explain 1.3% of the variability in dose. Clinical variables (Age, BMI, Enzyme inducers status and Amiodarone status) explained 22% of the variability in dose. This study developed an algorithm for acenocoumarol dosing using clinical and pharmacogenetic data.	Allele T is not associated with dose of acenocoumarol.	22911785	1448259332
APOE	rs7412	CT + TT	fenofibrate	efficacy	yes	Subjects carrying the E2 allele had a greater relative percentage decrease in non-high density lipoprotein-cholesterol concentration between baseline and 3 months of treatment, as compared to non-E2 subjects.	Genotypes CT + TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	12042669	1450974113
APOE	rs429358	C	donepezil	efficacy	no	as measured by total ADAS-Cog score obtained at baseline with that obtained at 36 months after MCI diagnosis (diff. ADAS-Cog score) but it was not significantly different. Authors write that "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." ADAS-Cog score difference at 36 months for ApoE4+ =–1.92, for those without E4 = –0.22.	Allele C is associated with increased response to donepezil in people with Alzheimer Disease as compared to allele T.	27567841	1450973000
APOE	rs429358	CC	hmg coa reductase inhibitors	efficacy	yes	Analysis of 859 subjects with AD (ROS/MAP dataset) and re-analysis of a clinical trial of simvastatin in 171 AD patients (simvastatin trial) found no significant difference in ADAS-cog scores between statin-treated patients and those treated with placebo. However, analysis of separate genotype subgroups found that E4/E4 subjects in the ROS/MAP dataset had significantly better cognitive function over a 10-year follow-up compared to those treated with placebo. Additionally, there was a non-significant trend in the simvastatin trial for subjects with the E4/E4 genotype who were treated with simvastatin to have lower ADAS-cog scores than E4/E4 patients treated with placebo.	Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Alzheimer Disease as compared to genotypes CT + TT.	28212683	1450973900
APOE	rs429358	C	ranibizumab	efficacy	no	Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing. P value was for "e4 carriers vs. others".	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	23842101	1450973680
APOE	rs429358	CC + CT	donepezil	efficacy	yes	In patients with moderate to severe Alzheimer's disease only (baseline Mini-Mental State Examination (MMSE) score < 20); in patients with mild Alzheimer's (MMSE >=20) no significant/borderline significant results were seen (p=0.05). Adjusted for gender, age, and baseline MMSE. After 6 months of treatment with cholinesterase inhibitors, those with the E4 allele were more likely to be a non-responder to treatment, as compared to those without the E4 allele. A responder was defined as a patient who showed improvement or no deterioration in cognition comparing MMSE scores at baseline with MMSE scores after 6 months.	Genotypes CC + CT is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to genotype TT.	24951635	1450973700
APOE	rs429358	CT	atorvastatin	efficacy	yes	Effect reported for E3/E4 compared to E3/E3 (there were no E4/E4 subjects in cohort).	Genotype CT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	25860945	1450973740